Kusatsu/Shiga Japan – September 12, 2025 – Takara Bio Inc. (Takara Bio) announced today that it has formulated “Takara Bio Group Long-Term Vison 2050” which expresses the future that Takara Bio Group (the Group) hopes to achieve and what it wants to be in 2050.
As the Group’s philosophy, “Contribution to the health of humankind through the development of revolutionary biotechnologies such as gene therapy,” the Group has aimed to be a global platform provider that is responsible for the infrastructure of the life science industry through our Reagent/Instruments and CDMO businesses.
However, the environment surrounding our business has changed dramatically, and the outlook is very uncertain due to the worldwide outbreak and end of the COVID-19 pandemic, heightened geopolitical risks caused by regional conflicts and other factors, and the shift to a bloc-based global economy.
Under these circumstances, the Group takes the Biotechnological Transformation (*) in all industries as an opportunity to grow and believes it is necessary to not only achieve linear growth in the Life Science Supporting Industry, but also create new businesses that achieve non-continuous quantum leap growth that is not an extension of the conventional growth.
In addition to the Medical and Healthcare field (Red Biotech), the Group will expand its activities to the Environment field (Gray Biotech), the Manufacturing and Energy field (White Biotech), the Marine field (Blue Biotech), and the Food and Plants field (Green Biotech). The Group intends to expand into the new business fields by utilizing our core competence, “DNA technologies” (technologies for analyzing ultra-low amounts of gene and cell and technologies for manufacturing high-performance and high-quality gene, cell and protein products in large quantities), in biomanufacturing.
The group’s sales target for fiscal year 2051 will be \100 billion in the our existing Life Science Supporting Industry business, and we will further expand activities in new businesses fields that contribute to solving global social issues which can only be addressed by biotechnology, to realize a quantum leap growth.
As “Human Health” and “Planetary Health” are deeply interconnected, the Group wants to maintain the health of the entire planet, including humankind. To this end, the Group will take challenges to realize “Planetary Health” by biotechnology-based innovation.
This Long-Term Vision 2050 serves a compass that guide the Group to the future.
Conceptual diagram of “Takara Bio Group Long-Term Vision 2050” (Figure)
Takara Holdings Inc. also announced “Takara Group Long-Term Vision 2050” today.
The details are showed in the web page of Takara Holdings Inc.
<Explanation of phrase>
* Biotechnological Transformation:
In analogy to the social changes brought about by digital transformation, the evolution of biotechnology should lead to major changes in the way society itself should be. It is advocated by Nippon Keidanren (Japan Business Federation) as a “Biotechnological Transformation (BX) Strategy”. It aims to solve social issues such as environmental degradation and resource constraints and achieve sustainable economic growth.
